{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:26:15Z","timestamp":1793316375781,"version":"4.5.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hydroxyurea is the standard therapy of chronic myelomonocytic leukemia (CMML) presenting with advanced myeloproliferative and\/or myelodysplastic features. Response to hypomethylating agents has been reported in heterogeneous series of CMML. We conducted a phase 2 trial of decitabine (DAC) in 39 patients with advanced CMML defined according to a previous trial. Median number of DAC cycles was 10 (range, 1-24). Overall response rate was 38% with 4 complete responses (10%), 8 marrow responses (21%), and 3 stable diseases with hematologic improvement (8%). Eighteen patients (46%) demonstrated stable disease without hematologic improvement, and 6 (15%) progressed to acute leukemia. With a median follow-up of 23 months, overall survival was 48% at 2 years. Mutations in ASXL1, TET2, AML1, NRAS, KRAS, CBL, FLT3, and janus kinase 2 (JAK2) genes, and hypermethylation of the promoter of the tumor suppressor gene TIF1\u03b3, did not predict response or survival on DAC therapy. Lower CJUN and CMYB gene expression levels independently predicted improved overall survival. This trial confirmed DAC efficacy in approximately 40% of CMML patients with advanced myeloproliferative or myelodysplastic features and suggested that CJUN and CMYB expression could be potential biomarkers in this setting. This trial is registered at EudraCT (eudract.ema.europa.eu) as #2008-000470-21 and www.clinicaltrials.gov as #NCT01098084.<\/jats:p>","DOI":"10.1182\/blood-2011-05-352039","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T22:19:18Z","timestamp":1312928358000},"page":"3824-3831","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":188,"title":["Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial"],"prefix":"10.1182","volume":"118","author":[{"given":"Thorsten","family":"Braun","sequence":"first","affiliation":[{"name":"H\u00f4pital Avicenne, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00e9matologie Clinique, University Paris XIII, Bobigny, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[{"name":"H\u00f4pital Avicenne, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00e9matologie Clinique, University Paris XIII, Bobigny, France;"},{"name":"Inserm Unit\u00e9 Mixte de Recherche (UMR) 1009, Institut Gustave Roussy; University Paris-Sud XI, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Renneville","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) de Lille, H\u00e9matologie biologique, University of Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"de Renzis","sequence":"additional","affiliation":[{"name":"CHU Estaing, H\u00e9matologie clinique adulte et th\u00e9rapie cellulaire, Clermont Ferrand, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Dreyfus","sequence":"additional","affiliation":[{"name":"H\u00f4pital Cochin, AP-HP, H\u00e9matologie Clinique, University Paris V, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[{"name":"Centre Hospitalier (CH) du Mans, H\u00e9matologie et Oncologie, Le Mans, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"H\u00f4pital Haut-L\u00e9v\u00eaque, Maladies du Sang, University of Bordeaux, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[{"name":"Institut Paoli-Calmette, D\u00e9partement d'H\u00e9matologie, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Toma","sequence":"additional","affiliation":[{"name":"H\u00f4pital Henri Mondor, AP-HP, H\u00e9matologie Clinique, University Paris XII, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Recher","sequence":"additional","affiliation":[{"name":"CHU de Toulouse, H\u00e9matologie Clinique, H\u00f4pital Purpan, Inserm UMR 1037, Cancer Research Center of Toulouse, Centre National de la Recherche Scientifique (CNRS) ERL 5294, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Royer","sequence":"additional","affiliation":[{"name":"CHU Amiens, Service d'H\u00e9matologie Clinique, University of Amiens, Amiens, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Joly","sequence":"additional","affiliation":[{"name":"CH Sud Francilien, H\u00e9matologie Clinique, Corbeil Essonnes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vekhoff","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Antoine, AP-HP, H\u00e9matologie Clinique, University Paris IV, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Lafon","sequence":"additional","affiliation":[{"name":"CHU Le Bocage, H\u00e9matologie Clinique, University of Burgundy, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Sanhes","sequence":"additional","affiliation":[{"name":"CH de Perpignan, H\u00e9matologie Clinique, Perpignan, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Meurice","sequence":"additional","affiliation":[{"name":"Inserm Unit\u00e9 Mixte de Recherche (UMR) 1009, Institut Gustave Roussy; University Paris-Sud XI, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Or\u00e9ar","sequence":"additional","affiliation":[{"name":"Inserm Unit\u00e9 Mixte de Recherche (UMR) 1009, Institut Gustave Roussy; University Paris-Sud XI, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) de Lille, H\u00e9matologie biologique, University of Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Gardin","sequence":"additional","affiliation":[{"name":"H\u00f4pital Avicenne, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00e9matologie Clinique, University Paris XIII, Bobigny, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ades","sequence":"additional","affiliation":[{"name":"H\u00f4pital Avicenne, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00e9matologie Clinique, University Paris XIII, Bobigny, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Fontenay","sequence":"additional","affiliation":[{"name":"Groupe Hospitalier (GH) Broca-Cochin-H\u00f4tel-Dieu, AP-HP, H\u00e9matologie biologique, Institut Cochin, Inserm U1016, CNRS UMR 8104, Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"H\u00f4pital Avicenne, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00e9matologie Clinique, University Paris XIII, Bobigny, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Droin","sequence":"additional","affiliation":[{"name":"Inserm Unit\u00e9 Mixte de Recherche (UMR) 1009, Institut Gustave Roussy; University Paris-Sud XI, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Solary","sequence":"additional","affiliation":[{"name":"Inserm Unit\u00e9 Mixte de Recherche (UMR) 1009, Institut Gustave Roussy; University Paris-Sud XI, Villejuif, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Groupe Francophone des My\u00e9lodysplasies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111807535547800_B1","first-page":"76","article-title":"Chronic myelomonocytic leukemia.","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Orazi","year":"2008"},{"issue":"1","key":"2019111807535547800_B2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2009-05-224352","article-title":"Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia.","volume":"115","author":"Droin","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111807535547800_B3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia.","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"24","key":"2019111807535547800_B4","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"key":"2019111807535547800_B5","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2011.08631.x","article-title":"Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.","author":"Bacher","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111807535547800_B6","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/sj.leu.2402891","article-title":"Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML).","volume":"17","author":"Tessema","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"2019111807535547800_B7","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1172\/JCI45213","article-title":"Transcription intermediary factor 1\u03b3 is an epigenetically-regulated tumor suppressor gene in human chronic myelomonocytic leukemia.","volume":"121","author":"Aucagne","year":"2011","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111807535547800_B8","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111807535547800_B9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","article-title":"Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival.","volume":"68","author":"Worsley","year":"1988","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111807535547800_B10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","article-title":"Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases.","volume":"6","author":"Fenaux","year":"1988","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807535547800_B11","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1080\/10428190701216386","article-title":"Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M. D. Anderson Prognostic Scoring System.","volume":"48","author":"Beran","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111807535547800_B12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111807535547800_B13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"17","key":"2019111807535547800_B14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","article-title":"TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.","volume":"94","author":"Kosmider","year":"2009","journal-title":"Haematologica"},{"issue":"24","key":"2019111807535547800_B15","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111807535547800_B16","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"2019111807535547800_B17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2008.366","article-title":"Outcome of allo-SCT for chronic myelomonocytic leukemia.","volume":"43","author":"Ocheni","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111807535547800_B18","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia: Groupe Francais des Myelodysplasies and European CMML Group.","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"issue":"7","key":"2019111807535547800_B19","first-page":"1129","article-title":"Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia.","volume":"5","author":"Fenaux","year":"1987","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807535547800_B20","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.","volume":"17","author":"Beran","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807535547800_B21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/cncr.21699","article-title":"Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"2019111807535547800_B22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia.","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111807535547800_B23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"2019111807535547800_B24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"issue":"3","key":"2019111807535547800_B25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111807535547800_B26","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia.","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"12","key":"2019111807535547800_B27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111807535547800_B28","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2019111807535547800_B29","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/leu.2010.144","article-title":"The most commonly reported variant in ASXL1 (c. 1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.","volume":"24","author":"Abdel-Wahab","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019111807535547800_B30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2141.2010.08226.x","article-title":"Current therapeutic approaches for patients with myelodysplastic syndromes.","volume":"150","author":"Greenberg","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111807535547800_B31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.V76.6.1214.1214","article-title":"RAS mutations are rare events in Philadelphia chromosome-negative\/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia.","volume":"76","author":"Hirsch-Ginsberg","year":"1990","journal-title":"Blood"},{"issue":"10","key":"2019111807535547800_B32","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2019111807535547800_B33","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1182\/blood-2007-07-103960","article-title":"Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.","volume":"111","author":"Oki","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111807535547800_B34","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood-2009-08-238360","article-title":"Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia.","volume":"116","author":"Bies","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111807535547800_B35","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/sj.leu.2402891","article-title":"Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML).","volume":"17","author":"Tessema","year":"2003","journal-title":"Leukemia"},{"issue":"17","key":"2019111807535547800_B36","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-09-4474","article-title":"Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.","volume":"70","author":"Si","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"2019111807535547800_B37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/leu.2010.266","article-title":"Synergistic induction of PI-PLC\u03b21 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.","volume":"25","author":"Follo","year":"2011","journal-title":"Leukemia"},{"issue":"13","key":"2019111807535547800_B38","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2009-02-203547","article-title":"Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.","volume":"114","author":"Fandy","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111807535547800_B39","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1128\/MCB.01330-08","article-title":"Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.","volume":"29","author":"Yang","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"6353","key":"2019111807535547800_B40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/354494a0","article-title":"Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.","volume":"354","author":"Smeal","year":"1991","journal-title":"Nature"},{"issue":"7","key":"2019111807535547800_B41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrc2439","article-title":"MYB function in normal and cancer cells.","volume":"8","author":"Ramsay","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019111807535547800_B42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","article-title":"Hypomethylating agents and other novel strategies in myelodysplastic syndromes.","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111807535547800_B43","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1002\/cncr.25774","article-title":"Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.","volume":"117","author":"Silverman","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"2019111807535547800_B44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/gcc.20877","article-title":"DNMT3B gene amplification predicts resistance to DNA demethylating drugs.","volume":"50","author":"Sim\u00f3-Riudalbas","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2019111807535547800_B45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2\u2032-deoxycytidine in human cancer cell lines.","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111807535547800_B46","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","article-title":"Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.","volume":"66","author":"Gore","year":"2006","journal-title":"Cancer Res"},{"issue":"6","key":"2019111807535547800_B47","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1365-2141.2009.08061.x","article-title":"Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.","volume":"148","author":"Scott","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111807535547800_B48","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1073\/pnas.88.6.2351","article-title":"Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.","volume":"88","author":"Calabretta","year":"1991","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/14\/3824\/1316615\/zh804011003824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/14\/3824\/1316615\/zh804011003824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T16:41:01Z","timestamp":1712680861000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/14\/3824\/28724\/Molecular-predictors-of-response-to-decitabine-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,6]]},"references-count":48,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2011,10,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-352039","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.12882957.14170055","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,6]]}}}